Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.48 |
| ▸ | LOX | P28300 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 4/20 | 0.42 |
| ▸ | F10 | P00742 | 4/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.42 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15871857 | 0.89 | LOXL2 (0.55) | LOXL2LOXBLMF2F10 | |
| SCHEMBL2521152 | 0.82 | LTA4H (0.58) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL8972092 | 0.81 | TSHR (0.47) | LOXL2LOXF2F10PRSS1 | |
| SCHEMBL25946356 | 0.81 | F2 (0.42) | LOXL2LOXF2F10PRSS1 | |
| SCHEMBL13670534 | 0.76 | LOXL2 (0.41) | LOXL2LOXBLMF2F10 | |
| SCHEMBL6316219 | 0.75 | F2 (0.40) | LOXL2LOXBLMF2F10 | |
| SCHEMBL8941611 | 0.75 | PTPRZ1 (0.46) | LOXL2LOXBLMF2F10 | |
| SCHEMBL8941674 | 0.75 | F2 (0.46) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL16511926 | 0.74 | F2 (0.48) | BLMF2F10PRSS1PRSS2 | |
| SCHEMBL9682231 | 0.74 | F2 (0.39) | LOXL2LOXBLMF2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8617723-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2013-12-31 | — | — | US | disclosed |
| US-20110012100-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2011-01-20 | — | — | US | disclosed |
| EP-2254896-A1 | METAL COMPLEXES | Merck Patent GmbH (DE) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009118087-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110012100-A1 | METAL COMPLEXES | AP1M1, AP3M1, SOD1 | LOXL2 2818/4885LOX 3424/4885BLM 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.